iVascular’s Post

View organization page for iVascular, graphic

28,317 followers

BARISTA Trial first clinical data of #Restorer BMS include 100% technical success and impressive outcomes: 96.9% primary patency and 98.5% fTLR at 12-month follow-up. Restorer proves efficacy and safety for aortoiliac lesions thanks to its advanced design. BARISTA enrolment has been completed with 200 patients from 14 centers.   #iVascular #EndovascularTherapy #MedicalInnovation

  • No alternative text description for this image

Buen comienzo, esperemos que la TLR y la permeabilidad primaria se mantengan en el tiempo.

Like
Reply

To view or add a comment, sign in

Explore topics